Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

MICHAEL MCCOY The Swiss drug firm Novartis has agreed to acquire a company it cofounded. Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front ...

despite a mid-stage stroke trial miss – as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial ...

as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...

After hours: February 21 at 5:25:54 PM EST Loading Chart for KYTX ...

After hours: February 21 at 6:43:58 PM EST Loading Chart for RPTX ...

Sanofi S.A. Part Cert 0.02% €8.03M ...